Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab

Patientswith ataxia telangiectasia (AT)withmalignancies facepoor prognosisdueto increasedtreatment-relatedtoxicity. Here, wereporta 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity. (C) 2015 Wiley Periodicals, Inc.